News | May 31, 2025
QMS Medical Allied Services posts 134.36% jump in consolidated PAT in Q4 FY25
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
For FY25, Revenue from operation grew 28.8 per cent YoY to Rs. 70.1 crore
During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
For over 13 years, Star Imaging has pioneered the introduction of next-generation radiology technologies in Pune
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
She has held senior positions at Coca-Cola in China and PepsiCo in India
Scores highest PAT of Rs. 118 crore in FY25
Subscribe To Our Newsletter & Stay Updated
